Archives of Neuroscience

Published by: Kowsar

Serum Uric Acid Levels in Different Phases of Acute Severe Manic and Depressed Patients

Mojtaba Keshavarz 1 , * , Fatemeh Khosravizadegan 2 , 3 and Alireza Bibak 3
Authors Information
1 Department of Pharmacology, School of Medicine, Bushehr University of Medical Sciences, Bushehr, IR Iran
2 Department of Psychiatry, School of Medicine, Bushehr University of Medical Sciences, Bushehr, IR Iran
3 Department of Psychiatry, Fatemeh Zahra Hospital, School of Medicine, Bushehr University of Medical Sciences, Bushehr, IR Iran
Article information
  • Archives of Neuroscience: April 01, 2016, 3 (2); e30236
  • Published Online: December 28, 2015
  • Article Type: Research Article
  • Received: June 1, 2015
  • Revised: November 17, 2015
  • Accepted: November 24, 2015
  • DOI: 10.5812/archneurosci.30236

To Cite: Keshavarz M, Khosravizadegan F, Bibak A. Serum Uric Acid Levels in Different Phases of Acute Severe Manic and Depressed Patients, Arch Neurosci. 2016 ; 3(2):e30236. doi: 10.5812/archneurosci.30236.

Copyright © 2015, Tehran University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Andreazza AC, Kauer-Sant'anna M, Frey BN, Bond DJ, Kapczinski F, Young LT, et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord. 2008; 111(2-3): 135-44[DOI][PubMed]
  • 2. Kowatch RA, Fristad M, Birmaher B, Wagner KD, Findling RL, Hellander M, et al. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005; 44(3): 213-35[PubMed]
  • 3. Chaudhari K, Khanzode S, Khanzode S, Dakhale G, Saoji A, Sarode S. Clinical correlation of alteration of endogenous antioxidant-uric acid level in major depressive disorder. Indian J Clin Biochem. 2010; 25(1): 77-81[DOI][PubMed]
  • 4. Le-Niculescu H, McFarland MJ, Ogden CA, Balaraman Y, Patel S, Tan J, et al. Phenomic, convergent functional genomic, and biomarker studies in a stress-reactive genetic animal model of bipolar disorder and co-morbid alcoholism. Am J Med Genet B Neuropsychiatr Genet. 2008; 147B(2): 134-66[DOI][PubMed]
  • 5. Teixeira AL, Barbosa IG, Machado-Vieira R, Rizzo LB, Wieck A, Bauer ME. Novel biomarkers for bipolar disorder. Expert Opin Med Diagn. 2013; 7(2): 147-59[DOI][PubMed]
  • 6. Machado-Vieira R, Soares JC, Lara DR, Luckenbaugh DA, Busnello JV, Marca G, et al. A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J Clin Psychiatry. 2008; 69(8): 1237-45[PubMed]
  • 7. Rosa AR, Singh N, Whitaker E, de Brito M, Lewis AM, Vieta E. Altered plasma glutathione levels in bipolar disorder indicates higher oxidative stress; a possible risk factor for illness onset despite normal brain-derived neurotrophic factor (BDNF) levels. Psychol Med. 2014; 27: 1-10[DOI]
  • 8. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol. 2008; 11(6): 851-76[DOI][PubMed]
  • 9. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011; 35(3): 804-17[DOI][PubMed]
  • 10. Barden N, Harvey M, Gagne B, Shink E, Tremblay M, Raymond C, et al. Analysis of single nucleotide polymorphisms in genes in the chromosome 12Q24.31 region points to P2RX7 as a susceptibility gene to bipolar affective disorder. Am J Med Genet B Neuropsychiatr Genet. 2006; 141B(4): 374-82[DOI][PubMed]
  • 11. Sperlagh B, Csolle C, Ando RD, Goloncser F, Kittel A, Baranyi M. The role of purinergic signaling in depressive disorders. Neuropsychopharmacol Hung. 2012; 14(4): 231-8[PubMed]
  • 12. Akhondzadeh S, Milajerdi MR, Amini H, Tehrani-Doost M. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar Disord. 2006; 8(5 Pt 1): 485-9[DOI][PubMed]
  • 13. De Berardis D, Conti CM, Campanella D, Carano A, Di Giuseppe B, Valchera A, et al. Evaluation of plasma antioxidant levels during different phases of illness in adult patients with bipolar disorder. J Biol Regul Homeost Agents. 2008; 22(3): 195-200[PubMed]
  • 14. Anumonye A, Reading HW, Knight F, Ashcroft GW. Uric-acid metabolism in manic-depressive illness and during lithium therapy. Lancet. 1968; 1(7555): 1290-3[PubMed]
  • 15. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978; 133: 429-35[PubMed]
  • 16. Lee Y, Han D, Noh D, Kim S, Na C. Correlation between clinical symptoms, serum uric acid level, and beta wave of EEG in patients with bipolar disorder. Eur Neuropsychopharmacol. 2010; 20
  • 17. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci. 2010; 64(4): 341-57[DOI][PubMed]
  • 18. Wen S, Cheng M, Wang H, Yue J, Wang H, Li G, et al. Serum uric acid levels and the clinical characteristics of depression. Clin Biochem. 2012; 45(1-2): 49-53[DOI][PubMed]
  • 19. American Psychiatric Association . diagnostic criteria from dsM-iV-tr. 2000; [DOI]
  • 20. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23: 56-62[PubMed]
  • 21. McIntyre RS, Mancini DA, McCann S, Srinivasan J, Sagman D, Kennedy SH. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord. 2002; 4(3): 207-13[PubMed]
  • 22. Reddy R, Keshavan M, Yao JK. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res. 2003; 62(3): 205-12[PubMed]
  • 23. Belcastro V, D'Egidio C, Striano P, Verrotti A. Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Res. 2013; 107(1-2): 1-8[DOI][PubMed]
  • 24. Stinefelt B, Leonard SS, Blemings KP, Shi X, Klandorf H. Free radical scavenging, DNA protection, and inhibition of lipid peroxidation mediated by uric acid. Ann Clin Lab Sci. 2005; 35(1): 37-45[PubMed]
  • 25. Bowman GL, Shannon J, Frei B, Kaye JA, Quinn JF. Uric acid as a CNS antioxidant. J Alzheimers Dis. 2010; 19(4): 1331-6[DOI][PubMed]
  • 26. Kutzing MK, Firestein BL. Altered uric acid levels and disease states. J Pharmacol Exp Ther. 2008; 324(1): 1-7[DOI][PubMed]
  • 27. Ozcan ME, Gulec M, Ozerol E, Polat R, Akyol O. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol. 2004; 19(2): 89-95[PubMed]
  • 28. Shao L, Young LT, Wang JF. Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol Psychiatry. 2005; 58(11): 879-84[DOI][PubMed]
  • 29. Kim TS, Pae CU, Yoon SJ, Jang WY, Lee NJ, Kim JJ, et al. Decreased plasma antioxidants in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2006; 21(4): 344-8[DOI][PubMed]
  • 30. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol. 2005; 58(5): 797-800[DOI][PubMed]
  • 31. Yu ZF, Bruce-Keller AJ, Goodman Y, Mattson MP. Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res. 1998; 53(5): 613-25[PubMed]
  • 32. Kesebir S, Tatlidil Yaylaci E, Suner O, Gultekin BK. Uric acid levels may be a biological marker for the differentiation of unipolar and bipolar disorder: the role of affective temperament. J Affect Disord. 2014; 165: 131-4[DOI][PubMed]
  • 33. Chung KH, Huang CC, Lin HC. Increased risk of gout among patients with bipolar disorder: a nationwide population-based study. Psychiatry Res. 2010; 180(2-3): 147-50[DOI][PubMed]
  • 34. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006; 354(12): 1243-52[DOI][PubMed]
  • 35. Insel TR, Scolnick EM. Cure therapeutics and strategic prevention: raising the bar for mental health research. Mol Psychiatry. 2006; 11(1): 11-7[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments